Out­look's shares crash as wet AMD drug flunks Phase 3 test

Af­ter the FDA re­ject­ed Out­look Ther­a­peu­tics’ oph­thalmic for­mu­la­tion of be­va­cizum­ab last year, the ex­per­i­men­tal ther­a­py has now failed a late-stage study in pa­tients with a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER